We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+29.04%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$514M
AUM Growth
-$44.2M
Cap. Flow
-$142M
Cap. Flow %
-27.71%
Top 10 Hldgs %
56.71%
Holding
50
New
12
Increased
6
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$16.4M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$11.6M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$9.99M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.58M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.38M

Top Sells

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$35.9M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$29M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$24.8M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.6M
5
ZGNX
Zogenix, Inc.
ZGNX
+$19.3M

Sector Composition

Rank Sector Weight
1 Healthcare 68.75%
2 Technology 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APYX icon
26
Apyx Medical
APYX
$173M
$6.18M 1.2%
1,829,441
-1,094,574
-37% -$2.83M
ADMS
27
DELISTED
Adamas Pharmaceuticals
ADMS
$5.43M 1.06%
256,340
-1,960,011
-88% -$35.9M
MCRB icon
28
PUT
Seres Therapeutics
MCRB
$46.8M
$4.41M 0.86%
+13,750
New +$3.76M
AMRN
29
Amarin Corp
AMRN
$299M
$3.7M 0.72%
52,841
-35,659
-40% -$2.53M
NVCR icon
30
NovoCure
NVCR
$1.73B
$3.53M 0.69%
+177,666
New +$3.49M
MYOV
31
DELISTED
Myovant Sciences Ltd.
MYOV
$3.53M 0.69%
228,008
-19,891
-8% -$242K
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.83M 0.55%
41,649
+759
+2% +$62K
CNXR
33
DELISTED
Connecture, Inc.
CNXR
$2.77M 0.54%
4,127,232
– –
AGRX
34
DELISTED
Agile Therapeutics
AGRX
$1.62M 0.32%
+182
New +$1.4M
ARDX icon
35
Ardelyx
ARDX
$1.22B
$691K 0.13%
+123,316
New +$650K
STRM
36
DELISTED
Streamline Health Solutions
STRM
$191K 0.04%
8,676
– –
SIOX
37
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$67K 0.01%
+1,210
New +$204K
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-276,800
Closed -$23.6M
DVAX
39
DELISTED
Dynavax Technologies
DVAX
– –
-435,500
Closed -$4.2M
FOLD
40
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-12,400
Closed -$125K
INSM icon
41
Insmed
INSM
$21.4B
– –
-538,473
Closed -$9.24M
PCRX icon
42
Pacira BioSciences
PCRX
$1.04B
– –
-300,000
Closed -$14.3M
SAGE
43
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-51,600
Closed -$4.11M
TVRD
44
Tvardi Therapeutics
TVRD
$19.7M
– –
-1,374
Closed -$761K
TVRD
45
PUT
Tvardi Therapeutics
TVRD
$19.7M
– –
-7,539
Closed -$4.18M
LUMO
46
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-121,428
Closed -$8.03M
SGEN
47
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-249,500
Closed -$12.9M
PTLA
48
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-216,200
Closed -$12.1M
ARDM
49
DELISTED
Aradigm Corp Common Stock
ARDM
– –
-637,279
Closed -$835K
NDRM
50
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-311,000
Closed -$9.3M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2017 Portfolio in Review

As of Q3 2017, Great Point Partners held 50 positions worth $514M, down 7.9% from $558M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Great Point Partners withdrew a net $142M in Q3 2017, closing 13 positions and reducing 15 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $23.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 79% a quarter earlier, followed by Technology.

Against the trend, Great Point Partners opened a new position in Kura Oncology worth $26.2M.

  • Great Point Partners's largest Q3 2017 buy was Kura Oncology: 1,750,887 shares worth $26.2M.
  • Great Point Partners added most to Iovance Biotherapeutics in Q3 2017, an estimated $11.6M increase.
  • Great Point Partners's biggest Q3 2017 reduction was Adamas Pharmaceuticals, cutting an estimated $35.9M.
  • Great Point Partners fully exited Alnylam Pharmaceuticals in Q3 2017, selling an estimated $23.6M.
  • Great Point Partners's ten largest holdings make up 57% of its $514M portfolio in Q3 2017.
  • Great Point Partners opened 12 new positions and closed 13 in Q3 2017.
  • Great Point Partners's portfolio value fell 7.9% quarter-over-quarter to $514M.

Based on Great Point Partners's 13F filing for Q3 2017, filed 14 Nov 2017.